Early introduction of A1P1 protein augmentation therapy to patients with emphysema may be beneficial in the treatment of the condition, according to a study from researchers from the Royal College of Surgeons in Ireland (RCSI) published in The Lancet.

Professor Gerry McElvaney, Department of Medicine, RCSI led a team of international colleagues to scientifically validate that A1P1 protein augmentation therapy is successful in slowing the progression of emphysema and loss of lung density, signalling a breakthrough in the treatment of hereditary emphysema.

Read more at www.healthcanal.com